CT26-hCD24
Strain Information
Validation Data
Figure 1. Expression of human CD24 on CT26-hCD24 cells was confirmed by flow cytometry.
CT26-hCD24 cells and wild type CT26 cells were stained with species-specific anti- CD24 antibodies. FACS analysis shows that human CD24 but not mouse CD24 was exclusively detectable on CT26-hCD24 cells.
Figure 2. In vivo tumor growth curves in humanized CT26-hCD24 syngeneic model.
BALB/c mice were subcutaneously injected 1×106 CT26-hCD24 cells compared with wild type CT26 cells as control. Tumor growth was monitored by measuring tumor size from day 5 after subcutaneous implantation.
Data shows that there were no significant differences between CT26-hCD24 cells and wild type CT26 cells in either tumorigenicity or tumor growth.
Figure 3. FACS analysis of CD24 expression on tumor cells derived from humanized CT26-hCD24 syngeneic model with species-specific anti-CD24 antibodies.
Data shows that human CD24 knock-in tumor exclusively express human CD24 but not mouse CD24.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
